clinical trial · NCT07183189
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase3·recruiting·n = 576
Non-small Cell Lung CancerSHR-A2009 ; AumolertinibAumolertinib
brief summary
This study is a randomized, controlled, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of SHR-A2009 combined with aumolertinib versus aumolertinib monotherapy in treatment-naïve subjects with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer.
started
Oct 30, 2025
primary completion
Nov 1, 2032
completion
Dec 1, 2032
last updated
Apr 14, 2026
official title
A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib as First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol